Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

To join this study, people generally need to be quite well and able to carry out their daily activities. You must have pancreatic cancer that has spread or is locally advanced, and your cancer needs to be clearly visible on scans so doctors can measure how it's responding to the treatment. Also, a sample of your tumour will be checked to make sure certain immune cells are present.

There are several reasons why someone might not be able to join. For example, if your cancer has spread to your brain or spinal cord and is causing symptoms, or if you have certain heart problems, you likely won't be able to participate. You also can't join if you've had certain serious blood clots or a major heart event recently.

Additionally, you can't have active serious infections like hepatitis, HIV, or tuberculosis, and your body's main organs (like your liver, kidneys, and bone marrow) need to be working properly. If you already have a known genetic change in your pancreatic cancer for which there's a standard and preferred treatment, you also won't be eligible for this study.

If you join this study, you will receive a combination of medicines: AZD0171, durvalumab, gemcitabine, and nab-paclitaxel. These will be given according to a specific schedule decided by the study doctors. You will have regular hospital visits for these treatments and check-ups.

During your time in the study, you'll have various assessments. This includes physical exams, blood tests to check your general health and how the drugs are working, and scans (like CT scans) to see how your cancer is responding. You will also need to provide tissue samples from your tumour if you haven't already. These tests are done to monitor your health, look for side effects, and see if the treatment is effective.

Treatment will continue for as long as it is helping to control your cancer and as long as you are not experiencing side effects that are too difficult to manage. You will also be followed up by the study team even after you stop treatment to monitor your health. The total duration of your participation, including follow-up, will depend on how you respond to the treatment.